Abstract
The main characteristics of clindamycin are adequate for treatment of osteoarticular infections (OAI): good bone diffusion, broad spectrum of antibacterial activity and oral use. A number of 61 patients was included in an observational retrospective study of efficacy and tolerance. Prosthetic infections accounted for 50.8% of the cases and chronic osteitis for 36.1%. The causative micro-organisms were Staphylococci (72.2%) and Streptococci (15.3%); 86.5% of these strains were susceptible to erythromycin, 9.6% were erythromycin resistant and susceptible to lincomycin. Clindamycin was associated with either ofloxacine, rifampicin, or teicoplanin in 88.5% and the average course duration was 101 days. A surgical procedure was performed in 84% of cases. Complete cure was obtained in 91.1% at 18 months of follow up. Only one cutaneous rash and one Clostridium difficile-associated diarrhea occurred. The other adverse effects were gastrointestinal in 36%, cutaneous in 6.6%, and hematological in 1.6%, but did not lead to discontinuation of therapy. Clindamycin can be used in OAI in association with or as an alternative to rifampicin, fluoroquinolones, or glycopeptides according to microbiological data.
References
Jul 1, 1978·Archives of Surgery·R E Condon, M J Anderson
Oct 1, 1977·American Journal of Diseases of Children·W RodriguezP Moskowitz
Dec 1, 1990·Antimicrobial Agents and Chemotherapy·R N Greenberg
Jun 1, 1990·The Journal of Infectious Diseases·L DallJ Lane
Dec 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P DellamonicaH B Drugeon
Feb 1, 1982·Southern Medical Journal·S L KaplanR D Feigin
Oct 1, 1995·Irish Journal of Medical Science·A Lane-O'Kelly, A C Moloney
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·M DrancourtD Raoult
Apr 3, 1997·The New England Journal of Medicine·D P Lew, F A Waldvogel
Aug 1, 1997·Annals of the Rheumatic Diseases·C J KaandorpB A Dijkmans
Dec 22, 1999·Antimicrobial Agents and Chemotherapy·R N GreenbergR W Pectol
Dec 26, 2001·The Journal of Antimicrobial Chemotherapy·E SennevilleY Mouton
Aug 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E. BernardP. Dellamonica
Jul 18, 2003·The Pediatric Infectious Disease Journal·Gerardo Martínez-AguilarSheldon L Kaplan
Apr 21, 2005·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Luca LazzariniJon T Mader
Apr 23, 2005·The Journal of Antimicrobial Chemotherapy·John Ng, Iain B Gosbell
Sep 20, 2006·Clinical Therapeutics·Eric SennevilleYves Mouton
Jan 3, 2007·The Journal of Infection·Naval G DaverA Clinton White
Citations
Dec 17, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R FarhadP Boileau
Oct 21, 2009·Antimicrobial Agents and Chemotherapy·Valérie ZellerNicole Desplaces
Aug 11, 2011·Infection·M MalletX Lemaire
Sep 16, 2011·Scandinavian Journal of Infectious Diseases·Jaroslaw CzekajIlker Uçkay
Apr 4, 2015·Infection·Emmanuel CurisDominique Salmon
Jun 19, 2016·Pathogens and Disease·Jason TasseFrédéric Laurent
Apr 4, 2017·International Journal of Antimicrobial Agents·Piseth SengAndreas Stein
Jun 26, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Agnès DanréPierre-Marie Roger
Sep 9, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J CourjonP-M Roger
Nov 26, 2011·Expert Review of Anti-infective Therapy·Markus Pääkkönen, Heikki Peltola
Apr 11, 2012·British Journal of Clinical Pharmacology·Naïm BouazzaJean-Marc Tréluyer
Oct 17, 2019·Joint, Bone, Spine : Revue Du Rhumatisme·Christian LormeauLuca Semerano
Oct 26, 2020·Diagnostic Microbiology and Infectious Disease·Agathe BonnaireFirouzé Bani-Sadr
Jul 27, 2021·Journal of Orthopaedics·Hannes KuboHakan Pilge